Repligen to buy BioLife Solutions for about USD 1.5 billion, offers USD 31 a share
RGEN•Offer terms and financing
BioLife holders are to receive USD 11.25 in cash plus 0.1442 Repligen shares per share, valued at USD 31.
The consideration is split 64% stock and 36% cash, with the cash portion funded from cash on hand.
Timing and expected synergies
The transaction is expected to close in Q4 2026, subject to a BioLife stockholder vote and customary conditions.
Repligen projects at least USD 20 million in synergies in year one and at least USD 30 million in year two.
Repligen agrees to buy BioLife Solutions
Repligen agreed to buy BioLife Solutions in a deal valuing the target at about $1.5 billion.
